Fund Manager Peter Siris Spots Gold in China 9 comments
-
Font Size:
-
Print
- TweetThis
Writing for the New York Daily News Saturday, he singled out quite a few Chinese companies he likes including the following C.O.P. companies:
1) American Lorain (ALRC.OB);
2) China Yingxia [CYXI.OB];
3) China Agritech (CAGC.OB);
4) China Pharma (CPHI.OB);
5) China Solar (CSOL.OB);
6) China 3C Group (CHCG.OB); and
7) China Educational Alliance (CEUA.OB).
Former C.O.P. companies were also cited: Zhongpin (HOGS), Sutor (SUTR), Sinoenergy (SNEN.OB) and Ever-Glory (EVK).
A quote:
"I have visited the facilities of these companies and met with management — and I own these stocks in my investment fund. That means it is in my interest to see their prices go up. But I think there is still a lot more growth potential."
The full article here.
My Position: Long CYXI.OB, CPHI.OB, CHCG.OB.
Related Articles
|



























This article has 9 comments:
I own Cagc and Seed. Both have to be considered to be in the Fledgling Category. Sales, word of mouth, research, manufacturing, growth...only word of mouth is cheap.
Fertilizer and Genetically Modified seeds, Cagc may become another "Miracle Gro" and Seed another Monsanto or they may both go bankrupt.
To me revenue growth is the key and as long as I see it expanding, I know that eventually it will filter to the Bottom Line. There will be setbacks due to "earthquakes" or failed research or whatever, but if manangement reasonably explains the reasons for the short fall, I will continue to hold them. My time horizon is 5 years for a double.
"As to the peculiarity of the Chinese pharmaceutical environment, defaults in payments to pharmaceutical companies by state owned hospitals are a normal phenomenon. Over 90% of our drugs are sold to state owned hospitals, the greater our business with the hospital, the more payments are defaulted, although in actual fact, all the defaulted payments are eventually paid, it is only a matter of time."
You hit the nail on the head when you said that Chinese firms have done a poor job communicating with their investors. Many don't even have IR firms to supplement their own IR department staff who are often unqualified to relay the company's story in a manner that conveys the true advantages of investing in them.
My firm is actually proactively encouraging small and micro cap Chinese firms to join an established network in which they can get some more exposure. Of course, we invest in those companies and have an interest to see their stock prices increase.
It seems you have a pretty good handle on the situation and look forward to hearing more of your thoughts in the near future.